ECSP961693A - ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINE - Google Patents
ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINEInfo
- Publication number
- ECSP961693A ECSP961693A ECSP961693A ECSP961693A EC SP961693 A ECSP961693 A EC SP961693A EC SP961693 A ECSP961693 A EC SP961693A EC SP961693 A ECSP961693 A EC SP961693A
- Authority
- EC
- Ecuador
- Prior art keywords
- oral formulation
- cellulose
- hypromellose
- benzodiaceptine
- theno
- Prior art date
Links
Abstract
El invento se refiere a una formulación oral sólida que comprende alanzapina como ingrediente activo, mezclada intimamanete con un agente de carga; aglutinante, disgregante, un aglutinante seco para proporcionar fiabilidad adecuada, y un lubricante; en la que dicha formulación oral sólida está recubierta con un polímero seleccionado entre el grupo formado por hidroxipopil hipromelosa, hidroxietil celulosa, metilhidroxietil celulosa, carboxihipromelosa de sodio, hidroxipropil celulosa, polivinilpirrolidona, copolímero del éster dimetilaminoetílico metacrilato-éster dimetilaminoetílico metilacrilato, copolímero de etilacrilato-metilmetacrilato, hipromelosa y etilcelulosa.The invention relates to a solid oral formulation comprising alanzapine as an active ingredient, intimately mixed with a bulking agent; binder, disintegrant, a dry binder to provide adequate reliability, and a lubricant; wherein said solid oral formulation is coated with a polymer selected from the group consisting of hydroxypropyl hypromellose, hydroxyethyl cellulose, methylhydroxyethyl cellulose, sodium carboxypromellose, hydroxypropyl cellulose, polyvinylpyrrolidone, dimethylaminoethyl methacrylatyl-ethyl acrylate ester copolymer methyl methacrylate, hypromellose and ethyl cellulose.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ECSP961693 ECSP961693A (en) | 1996-03-21 | 1996-03-21 | ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINE |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ECSP961693 ECSP961693A (en) | 1996-03-21 | 1996-03-21 | ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINE |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP961693A true ECSP961693A (en) | 1997-09-22 |
Family
ID=42042425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP961693 ECSP961693A (en) | 1996-03-21 | 1996-03-21 | ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINE |
Country Status (1)
Country | Link |
---|---|
EC (1) | ECSP961693A (en) |
-
1996
- 1996-03-21 EC ECSP961693 patent/ECSP961693A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO4700474A1 (en) | ORAL FORMULATION OF 2-METHYL-THENO-BENZODIACEPINE | |
ES8200557A1 (en) | Sustained release pharmaceutical composition of solid medical material | |
AR049055A2 (en) | A QUICKLY REMOVABLE TABLET FOR ORAL ROUTE ADMINISTRATION | |
NO20011471D0 (en) | New oral sustained release formulations | |
FI962111A0 (en) | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | |
ES2159591T3 (en) | COMPOSITION OF CONTROLLED RELEASE. | |
UA94917C2 (en) | Topical formulations | |
DK1276470T3 (en) | Flavor-crushing coating composition | |
KR970025607A (en) | Sustained Release Nifedipine Formulation | |
PT1183014E (en) | ORAL PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED LIBERATION AND TISSUE DISSIMULATION | |
ECSP055748A (en) | CONTROLLED RELEASE COMPOSITIONS | |
AR022672A1 (en) | A PHARMACEUTICAL COMPOSITION IN THE FORM OF TABLETS OR CAPSULES THAT CONSTITUTE AN ORAL ADMINISTRATION METHOD OF A DRUG | |
ATE391495T1 (en) | MATRIX SYSTEM WITH DELAYED RELEASE FOR HIGHLY SOLUBLE ACTIVE INGREDIENTS | |
DE60023107D1 (en) | PREPARATIONS WITH IMPROVED CONTROLLED RELEASE | |
PT1318792E (en) | PROLONGED LIBERATION COMPOSITION CONTAINING CLARITHROMYCIN | |
ES2196620T3 (en) | FORMULATION OF PROLONGED RELEASE CONTAINING VENLAFAXINE. | |
AR021578A1 (en) | FORMULATION IN PRAVASTATIN PEARLS WITH ENTERIC COATING | |
EA200001201A2 (en) | Matrix tablet for prolonged release of trimetazidine | |
NO20055601L (en) | Pharmaceutical preparation in the form of a hydrogel for transdermal administration of active ingredients | |
RS50298B (en) | Directly compressibile matrix for controlled release of single daily doses of clarithromycin | |
AR021934A1 (en) | COMPOSITION OF ORAL ADMINISTRATION WITH CONTROLLED RELEASE OF AT LEAST ONE ANALGESIC | |
AU2697100A (en) | Pharmaceutical capsule compositions containing loratadine and pseudoephedrine | |
ECSP961693A (en) | ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINE | |
TR200200683T2 (en) | Oral controlled release formulations. | |
ES2150404T3 (en) | PHARMACEUTICAL COMPOSITIONS OF TIZOXANIDA AND NITOZOXANIDA. |